Use of tumor necrosis factor inhibitors in uveitis.

Published

Journal Article (Review)

PURPOSE OF REVIEW: Use of tumor necrosis factor-alpha blocking agents to treat chronic pediatric uveitis is becoming recognized as an important therapeutic modality. This review summarizes the rationale for this use, highlighting new studies of these agents in pediatric uveitis. RECENT FINDINGS: The majority of patients with pediatric uveitis either have idiopathic uveitis or uveitis associated with juvenile idiopathic arthritis. Ophthalmologic morbidity among these children is common. Most studies evaluating tumor necrosis factor-alpha blockade in pediatric uveitis are retrospective case series, with attendant limitations that are inherent to any retrospective study. Study of uveitis has been hampered by lack of standardization of disease and outcome measures, which has been addressed by uveitis experts with publication of consensus measures. Data to date suggest that tumor necrosis factor-alpha blockade is efficacious in refractory uveitis. Agents with direct tumor necrosis factor-alpha membrane receptor binding activity may be the most efficacious. There remain many unanswered questions in the treatment of pediatric uveitis, including optimal dosing regimen and long-term efficacy. SUMMARY: Tumor necrosis factor-alpha blocking agents play an important role in the treatment of chronic pediatric uveitis. Prospective comparative studies are needed so that we may better understand this role.

Full Text

Duke Authors

Cited Authors

  • Rabinovich, CE

Published Date

  • September 2007

Published In

Volume / Issue

  • 19 / 5

Start / End Page

  • 482 - 486

PubMed ID

  • 17762615

Pubmed Central ID

  • 17762615

International Standard Serial Number (ISSN)

  • 1040-8711

Digital Object Identifier (DOI)

  • 10.1097/BOR.0b013e32825f5481

Language

  • eng

Conference Location

  • United States